TW200635617A - Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form - Google Patents

Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form

Info

Publication number
TW200635617A
TW200635617A TW094140339A TW94140339A TW200635617A TW 200635617 A TW200635617 A TW 200635617A TW 094140339 A TW094140339 A TW 094140339A TW 94140339 A TW94140339 A TW 94140339A TW 200635617 A TW200635617 A TW 200635617A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical form
nucleic acid
acid active
producing
active ingredients
Prior art date
Application number
TW094140339A
Other languages
English (en)
Chinese (zh)
Inventor
Rosario Lizio
Hans-Ulrich Petereit
Trupti Dave
Michael Gottschalk
Original Assignee
Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roehm Gmbh filed Critical Roehm Gmbh
Publication of TW200635617A publication Critical patent/TW200635617A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW094140339A 2004-12-10 2005-11-16 Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form TW200635617A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004059792A DE102004059792A1 (de) 2004-12-10 2004-12-10 Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform

Publications (1)

Publication Number Publication Date
TW200635617A true TW200635617A (en) 2006-10-16

Family

ID=35709359

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094140339A TW200635617A (en) 2004-12-10 2005-11-16 Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form

Country Status (16)

Country Link
US (1) US8568778B2 (enExample)
EP (1) EP1824457B1 (enExample)
JP (1) JP5578764B2 (enExample)
KR (1) KR101319773B1 (enExample)
CN (1) CN101060835B (enExample)
BR (1) BRPI0515815B8 (enExample)
CA (1) CA2586597C (enExample)
DE (1) DE102004059792A1 (enExample)
ES (1) ES2569354T3 (enExample)
HU (1) HUE028793T2 (enExample)
IL (1) IL183753A (enExample)
MX (1) MX2007006343A (enExample)
PL (1) PL1824457T3 (enExample)
SI (1) SI1824457T1 (enExample)
TW (1) TW200635617A (enExample)
WO (1) WO2006061069A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
RU2009102262A (ru) * 2006-06-26 2010-08-10 Мьючуал Фармасьютикал Компани, Инк. (Us) Композиции активного агента, способы их получения и способы применения
CA2694089A1 (en) * 2007-07-16 2009-01-22 Northeastern University Therapeutic stable nanoparticles
DE102008048729A1 (de) * 2008-09-24 2010-03-25 Add Technologies Ltd Advanced Drug Delivery Multipartikuläre Tabletten und Verfahren zur deren Herstellung
US20130064896A1 (en) * 2009-12-29 2013-03-14 Laman Lynn Alani Gastroretentive Solid Oral Dosage Forms with Swellable Hydrophilic Polymer
US8765152B2 (en) 2010-02-25 2014-07-01 Evonik Roehm Gmbh Pharmaceutical or neutraceutical formulation
CN102250878B (zh) * 2011-06-03 2013-01-23 吉林大学 一种基于固相介质表面电荷的反转提取dna的方法
US9107851B2 (en) * 2012-10-15 2015-08-18 New Jersey Institute Of Technology Solventless mixing process for coating pharmaceutical ingredients
JP6912876B2 (ja) * 2016-10-06 2021-08-04 三洋化成工業株式会社 アクリル系医薬固形製剤用添加剤
WO2018170405A1 (en) * 2017-03-17 2018-09-20 Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
DE102020002360A1 (de) * 2020-04-18 2021-10-21 Friedrich-Schiller-Universität Jena Nanopartikel enthaltend Komplexe aus Nukleinsäuren und kationischen Copolymeren, Verfahren zu deren Herstellung und deren Verwendung zum Gentransfer in Zellen
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
CN117120020A (zh) * 2021-03-30 2023-11-24 塞拉尼斯伊娃高性能聚合物公司 用于递送核酸包封颗粒的植入式医疗器件
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
US12472148B2 (en) 2021-04-26 2025-11-18 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2023249087A1 (ja) * 2022-06-24 2023-12-28 三生医薬株式会社 医薬組成物およびその製造方法
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW209174B (enExample) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
AU7342296A (en) * 1995-10-25 1997-05-15 Octoplus Bv Cationic polyacrylates and poly(alkyl) acrylates or the corresponding acrylamides for use in synthetic transfection or blocking systems
GB9700624D0 (en) * 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US6730735B2 (en) * 1997-07-03 2004-05-04 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Conjugate of polyethylene glycol and chitosan
ATE366119T1 (de) 1999-08-09 2007-07-15 Dainippon Sumitomo Pharma Co Chitosanpulver enthaltende feste zubereitungen und verfahren zu deren herstellung
US7803392B2 (en) * 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
US20030017195A1 (en) * 2001-07-20 2003-01-23 Samir Mitragotri Method for oral drug delivery
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
DE10353186A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
DE102004036437A1 (de) 2004-07-27 2006-03-23 Röhm GmbH & Co. KG Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
DE102006035549A1 (de) 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht

Also Published As

Publication number Publication date
BRPI0515815B1 (pt) 2019-02-05
KR101319773B1 (ko) 2013-10-17
JP5578764B2 (ja) 2014-08-27
IL183753A (en) 2016-12-29
JP2008522989A (ja) 2008-07-03
MX2007006343A (es) 2007-07-04
DE102004059792A1 (de) 2006-06-14
CN101060835B (zh) 2013-01-02
BRPI0515815A (pt) 2008-08-05
EP1824457B1 (de) 2016-02-17
KR20070085894A (ko) 2007-08-27
CA2586597A1 (en) 2006-06-15
HK1110205A1 (en) 2008-07-11
PL1824457T3 (pl) 2016-07-29
BRPI0515815B8 (pt) 2021-05-25
SI1824457T1 (sl) 2016-06-30
WO2006061069A1 (de) 2006-06-15
CN101060835A (zh) 2007-10-24
HUE028793T2 (hu) 2017-01-30
ES2569354T3 (es) 2016-05-10
EP1824457A1 (de) 2007-08-29
IL183753A0 (en) 2007-09-20
CA2586597C (en) 2013-09-10
US20090280183A1 (en) 2009-11-12
US8568778B2 (en) 2013-10-29

Similar Documents

Publication Publication Date Title
TW200635617A (en) Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form
DE502004005154D1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein-wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
WO2006039499A3 (en) Method for improving the biovailability of orally delivered therapeutics
MX2022002952A (es) Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo.
CY1105908T1 (el) Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο
WO2006055142A8 (en) Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
ATE336232T1 (de) Arzneiform und verfahren ihrer herstellung
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
HRP20120264T1 (hr) Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
HUP0401714A2 (hu) Propiverin vagy gyógyászatilag elfogadható sóinak nyújtott hatóanyag-eladású, orális adagolási formái
NZ709754A (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
ATE441405T1 (de) Arzneiform und verfahren zu ihrer herstellung
WO2009041651A1 (ja) 速崩壊性固形製剤
WO2011084593A3 (en) Abuse-resistant formulations
WO2004069198A3 (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
JP2008505857A5 (enExample)
WO2005117843A3 (en) Sustained release preparations
JP2005503399A5 (enExample)
WO2008087323A8 (fr) Forme galenique pour l'administration par voie trans-muqueuse de paracetamol
CA2566931A1 (en) Tablets exhibiting reduced drug release variability
MX2008002512A (es) Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.
WO2009014372A3 (en) Dispersible tablet comprising coated drug-containing particles and method for the preparation thereof
JP2020536098A5 (enExample)
WO2005107702A3 (en) Sustained release, mucoadhesive vaginal pharmaceutical compositions